Expression of Cancer‐Testis Antigens MAGE ‐ A1 , MAGE ‐ A4 , NY ‐ ESO ‐1 and PRAME in Bone and Soft Tissue Sarcomas: The Experience From a Single Center in China

作者：Anni Chen, Yuling Qiu, Ying‐Tzu Yen, Wang Chun, Xiaolu Wang, Chunhua Li, Zijian Wei, Lin Li, Lixia Yu, Fangcen Liu, Rutian Li · 发表于：Cancer Medicine · 年份：2025 · DOI：10.1002/cam4.70750 · 被引用次数：3 · 研究领域：Immunotherapy and Immune Responses、vaccines and immunoinformatics approaches、Immune Cell Function and Interaction

OBJECTIVE: Sarcomas are a heterogeneous group of malignancies, low disease-control levels and the limited durability of responses have prompted the exploration of various novel immunotherapeutic approaches. To preliminarily explore the feasibility of cancer vaccines based on cancer testis antigen in the immunotherapy of sarcomas, we investigate the expression of Cancer/Testis Antigens (CTA) MAGE-A4, PRAME, MAGE-A1, KK-LC-1, and NY-ESO-1 in bone and soft tissue sarcomas, with the aim of assessing their potential for use in sarcoma immunotherapy and determining their expression levels in different subtypes. METHODS AND RESULTS: We employed immunohistochemistry and multiplex immunostaining microarrays (MI chips) to assess the expression of MAGE-A4, PRAME, MAGE-A1, KK-LC-1, and NY-ESO-1 in 21 cases of undifferentiated pleomorphic sarcoma (UPS), 26 cases of smooth muscle sarcoma, 28 cases of liposarcoma, 40 cases of osteosarcoma (OS), and 13 cases of chondrosarcoma. MAGE-A1 showed the highest expression in osteosarcoma (32.50%), while it was lower in liposarcoma and undifferentiated pleomorphic sarcoma (10.71% and 10.00%) and undetectable in chondrosarcoma. MAGE-A4 expression was elevated in osteosarcoma and undifferentiated pleomorphic sarcoma (40.00% and 33.00%), but lower in liposarcoma and smooth muscle sarcoma (17.00% and 33.00%). NY-ESO-1 expression was relatively low across all sarcoma subtypes. PRAME expression was highest in undifferentiated pleomorphic sarcoma (47.62%) a...